Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) System for Pediatric Patients with Hepatoblastoma: A Retrospective, Hospital-Based Cohort Study in South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: In 2017, the Children's Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) system was introduced. We aimed to evaluate the accuracy of CHIC-HS System for the prediction of event-free survival (EFS) in Korean pediatric patients with hepatoblastoma. Materials and methods: This two-center retrospective study included consecutive Korean pediatric patients with histopathologically confirmed hepatoblastoma from March 1988 through September 2019. We compared EFS among four risk groups according to the CHIC-HS system. Discriminatory ability of CHIC-HS system was also evaluated using optimism-corrected C-statistics. Factors associated with EFS were explored using multivariable Cox regression analysis. Results: We included 129 patients (mean age, 2.6±3.3 years; female:male, 63:66). The 5-year EFS rates in the very low, low, intermediate, and high-risk groups, according to the CHIC-HS system were 90.0%, 82.8%, 73.5%, and 51.3%, respectively. The CHIC-HS system aligned significantly well with EFS outcomes (p=0.004). The optimism-corrected C index of CHIC-HS was 0.644 (95% confidence interval [CI], 0.561 to 0.727). Age ≥ 8 (vs. age ≤ 2; hazard ratio [HR], 2.781; 95% CI, 1.187 to 6.512; p=0.018), PRE-Treatment EXTent of tumor (PRETEXT) stage IV (vs. PRETEXT I or II; HR, 2.774; 95% CI, 1.228 to 5.974; p=0.009), and presence of metastasis (HR, 2.886; 95% CI, 1.457 to 5.719; p=0.002), which are incorporated as the first three nodes in the CHIC-HS system, were independently associated with EFS. Conclusion: The CHIC-HS system aligned significantly well with EFS outcomes in Korean pediatric patients with hepatoblastoma. Age group, PRETEXT stage, and presence of metastasis were independently associated with EFS.
Abstract
Purpose: In 2017, the Children's Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) system was introduced. We aimed to evaluate the accuracy of CHIC-HS System for the prediction of event-free survival (EFS) in Korean pediatric patients with hepatoblastoma. Materials and methods: This two-center retrospective study included consecutive Korean pediatric patients with histopathologically confirmed hepatoblastoma from March 1988 through September 2019. We compared EFS among four risk groups according to the CHIC-HS system. Discriminatory ability of CHIC-HS system was also evaluated using optimism-corrected C-statistics. Factors associated with EFS were explored using multivariable Cox regression analysis. Results: We included 129 patients (mean age, 2.6±3.3 years; female:male, 63:66). The 5-year EFS rates in the very low, low, intermediate, and high-risk groups, according to the CHIC-HS system were 90.0%, 82.8%, 73.5%, and 51.3%, respectively. The CHIC-HS system aligned significantly well with EFS outcomes (p=0.004). The optimism-corrected C index of CHIC-HS was 0.644 (95% confidence interval [CI], 0.561 to 0.727). Age ≥ 8 (vs. age ≤ 2; hazard ratio [HR], 2.781; 95% CI, 1.187 to 6.512; p=0.018), PRE-Treatment EXTent of tumor (PRETEXT) stage IV (vs. PRETEXT I or II; HR, 2.774; 95% CI, 1.228 to 5.974; p=0.009), and presence of metastasis (HR, 2.886; 95% CI, 1.457 to 5.719; p=0.002), which are incorporated as the first three nodes in the CHIC-HS system, were independently associated with EFS. Conclusion: The CHIC-HS system aligned significantly well with EFS outcomes in Korean pediatric patients with hepatoblastoma. Age group, PRETEXT stage, and presence of metastasis were independently associated with EFS.
참고문헌 (14)
- Ranganathan S, "Hepatoblastoma and pediatric hepatocellular carcinoma : an update", Pediatr Dev Pathol, 23, pp.79~95 (2020)
- Carceller A, "Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma", J Pediatr Surg, 36, pp.755~759 (2001)
- Czauderna P, "Hepatoblastoma state of the art : pathology, genetics, risk stratification, and chemotherapy", Curr Opin Pediatr, 26, pp.19~28 (2014)
- Perilongo G, "Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma", N Engl J Med, 361, pp.1662~1670 (2009)
- Hiyama E, "Outcome and late complications of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol", J Clin Oncol, 38, pp.2488~2498 (2020)
- Haberle B, "High dose chemotherapy with autologous stem cell transplantation in hepatoblastoma does not improve outcome : results of the GPOH Study HB99", Klin Padiatr, 231, pp.283~290 (2019)
- Meyers RL, "Hepatoblastoma state of the art : pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation", Curr Opin Pediatr, 26, pp.29~36 (2014)
- Perilongo G, "Hepatoblastoma clinical research : lessons learned and future challenges", Pediatr Blood Cancer, 59, pp.818~821 (2012)
- Meyers RL, "Risk-stratified staging in paediatric hepatoblastoma : a unified analysis from the Children’s Hepatic tumors International Collaboration", Lancet Oncol, 18, pp.122~131 (2017)
- von Elm E, "Strengthening the Reporting of Observational Studies in Epidemiology(STROBE)statement : guidelines for reporting observational studies", BMJ, 335, pp.806~808 (2007)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Kang L, "Comparing two correlated C indices with right-censored survival outcome : a one-shot nonparametric approach", Stat Med, 34, pp.685~703 (2015)
- Wong MC, "The discriminatory capability of existing scores to predict advanced colorectal neoplasia : a prospective colonoscopy study of 5, 899 screening participants", Sci Rep, 6, pp.20080~ (2016)
- Czauderna P, "The Children’s Hepatic tumors International Collaboration(CHIC) : Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model", Eur J Cancer, 52, pp.92~101 (2016)